Prognostic value of circulating tumor DNA mutation panels to predict early recurrence and survival outcomes in early-stage breast cancer: a systematic review and meta-analysis.

Abstract excerpt

BACKGROUND: Early-stage breast cancer (BC) shows heterogeneous recurrence risk. Circulating tumor DNA (ctDNA) is promising non-invasive biomarker for minimal residual disease and recurrence prediction, though prognostic performance varies by assay and context. METHODS: Eligible studies on ctDNA-based recurrence and survival were identified through comprehensive searches, quality assessed, and analyzed using...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biomarkers, Tumor
• Share to Breast Neoplasms